INTRODUCTION
With no effective HIV vaccine available (1), considerable efforts have been made to develop microbicides as a strategy to curb sexual transmission of HIV. Unfortunately, many of the topical microbicides investigated to date have proved inactive or even increased the risk of HIV acquisition in clinical trials (2) (3) (4) (5) . One putative exception is the use of a vaginal gel containing tenofovir that has shown a 54% protection rate in the CAPRISA (Centre for the AIDS Program of Research in South Africa) 004 trial (6) . Unfortunately, however, a larger trial testing the same formula was stopped because of lack of efficacy (7) . The failure of topical microbicides has been attributed to lack of adherence, as well as the induction of inflammation and cytotoxic effects (3, 4) . Here, we explore the possibility that the HIV-enhancing activity of semen (8) (9) (10) (11) (12) (13) may diminish the efficacy of anti-HIV microbicides.
RESULTS
We previously established protocols that permit analysis of the infectivityenhancing activity of human semen by minimizing its cytotoxic effects (8, 12, 13) . To examine the ability of semen to enhance HIV infection of microbicide-treated cells, we modified this assay. As shown in Fig.  1A , either semen-or mock-treated CCR5-tropic HIV was added to TZM-bl reporter cells containing serial dilutions of the microbicides or antiviral drugs of interest. After 2 hours, the semen-containing inoculum was removed to prevent cytotoxic effects (8, 12, 13) , and fresh medium supplemented with antiviral drugs or microbicides was added. Infection rates were determined 3 days later by quantifying b-galactosidase activities in cellular lysates (Fig. 1A) .
We first analyzed the effect of semen on the antiviral activity of the microbicide SPL7013 (14, 15) . Development of this negatively charged dendrimer as a microbicide was terminated just recently because of adverse events (16) . As previously observed (8, 13) , HIV virion exposure to 10% semen increased low-dose HIV infectivity (0.05 ng of p24 antigen) by about 10-fold (Fig. 1B) . Thus, we used a 10-fold higher amount of mock-treated HIV (0.5 ng of p24 antigen) as an "infectivity-matched" control (Fig. 1B) . SPL7013 blocked infection at both doses of HIV with IC 50 (median inhibitory concentration) values of 1.2 ± 0.1 and 1.1 ± 0.2 mg/ml, respectively (Fig. 1, B and D, and Table 1 ). In contrast, SPL7013 was about 20-fold less effective against semen-exposed virus (IC 50 = 23 ± 1.9 mg/ml) (Fig. 1 , C and D, and Table 1 ). Notably, sementreated HIV still efficiently infected cells in the presence of 100 mg/ml of the SPL7013 dendrimer, a concentration that prevented mock-treated HIV infection entirely (Fig. 1 , B and C). Higher concentrations of the dendrimer were cytotoxic and could thus not be tested ( fig. S1A ). Next, we examined seven transmitter/founder (T/F) HIV-1 strains that are particularly relevant for HIV/AIDS transmission studies (17) . We found that 10% semen enhanced T/F virus infectivity by 7-to 16-fold (fig. S1B), and, on average, impaired the antiviral efficacy of SPL7013 by 60-fold (IC 50 increased from 0.9 ± 0.3 to 53.9 ± 16.3 mg/ml) (fig. S1, C and D).
To examine whether other anionic polymers are also less effective against semen-exposed virus, we analyzed polystyrene acid, polynaphthalene sulfonate, and cellulose sulfate. These compounds were among the first to be considered for microbicide development because of their potent in vitro activity (18) (19) (20) (21) but failed to prevent HIV transmission in people (2, 5, 22, 23) . Similar to the results described above for SPL7013, polystyrene acid ( fig. S2A) (Table 1) and generally failed to prevent semen-exposed virus infection. Again, concentrations ≥100 mg/ml could not be tested because of cytotoxic effects ( fig. S2D ). Thus, these three former microbicide candidates were poorly effective against HIV in the presence of semen.
Another class of candidate microbicides are neutralizing antibodies (nAbs). The gp41-specific nAb 2F5 ( Fig. 2A) efficiently blocked infection with HIV stocks containing 0.5 and 0.05 ng of p24 capsid antigen in the absence of semen with IC 50 values of 2.6 ± 0.3 and 2.7 ± 0.1 mg/ml, respectively ( Fig. 2A and Table 1 ). However, pretreatment of 0.05 ng of HIV with semen increased the IC 50 to 22.2 ± 1.2 mg/ml ( Fig. 2A and Table 1 ). Similar results were obtained for the 2G12 nAb targeting gp120 ( fig. S3A and Table 1 ). Thus, exposure of HIV to 10% semen decreased the antiviral efficacy of nAbs by almost 10-fold.
Polyanions and nAbs target HIV outside host cells. Remarkably, we found that antiviral drugs acting on intracellular targets, such as the HIV nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir disoproxil fumarate (Fig. 2B) , the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (Fig. 2C) , and the integrase inhibitor (INI) elvitegravir (Fig. 2D) , were also about 8-to 13-fold less effective against semen-exposed virus (Table 1) . For example, elvitegravir inhibited infection with both doses of HIV-1 at IC 50 values of 0.60 ± 0.07 nM and 0.72 ± 0.05 nM, respectively, whereas the IC 50 was increased to 5.6 ± 0.5 nM in the presence of semen ( Fig. 2D and Table 1 ). Finally, we analyzed the HIV protease inhibitor indinavir, which acts at a very late stage of the viral replication cycle. Similar to all other drugs tested so far, semen exposure reduced antiretroviral efficacy by 10-to 12-fold ( Fig. 2E and Table 1 ). In contrast to polyanions (figs. S1A and S2D), none of the nAbs or inhibitors against the viral enzymes were cytotoxic ( fig. S3 , B and C). These results indicate that semen reduces the sensitivity of HIV to multiple classes of antiretroviral therapeutics.
The findings described above were obtained from experiments performed in vitro in immortalized TZM-bl cells, or CEMx-M7 cells in the case of indinavir (Table 1) . To examine the effects of semen on the antiviral efficacy of microbicides in the primary target cells of HIV, human peripheral blood mononuclear cells (PBMCs) were supplemented with respective antiretroviral drugs and inoculated with either 5 ng of mock-or semen-exposed virus encoding a luciferase (and 50 ng of mock-treated virus as an infectivity-matched control). As previously reported (8, 13) , 10% semen enhanced HIV-1 infection of PBMCs by ∼9-fold (Fig. 3 , A to E, left panels, absence of drugs). Similar to the results obtained in the cell lines (Table 1) , the IC 50 values of polystyrene acid (Fig. 3A) , the nAb 2F5 (Fig. 3B) , tenofovir disoproxil fumarate (Fig. 3C) , elvitegravir (Fig. 3D) , and indinavir ( Fig. 3E ) increased by 7-to 20-fold if cells were inoculated with semen-exposed virus (Table 2) . Thus, semen reduced the antiviral efficacy of antiretroviral drugs in primary target cells for HIV.
In the absence of semen, the antiviral efficacy of the analyzed compounds was not markedly affected by the viral inocula (Table 1 , compare IC 50 values obtained by infection with 0.05 versus 0.5 ng of p24 virus). However, the IC 50 values after infection with 0.05 ng of semen-exposed virus were between 8-and 21-fold higher than those for the "p24-matched" (0.05 ng) and the infectivity-matched control (0.5 ng) (Table 1) . Thus, a specific property of semen rather than the increase in viral infection rates was responsible for the diminished antiviral efficacy. To examine whether the infectivity-enhancing activity of amyloid in semen may play a role, we tested the effect of a semenderived amyloid (8) (semen-derived enhancer of virus infection or SEVI) under the same experimental conditions. We found that the microbicides described above were all less active against SEVI-exposed HIV ( fig. S4 and Table 3 ). The differences in the IC 50 values (19-to 22-fold for polyanions; 7-to 17-fold for remaining classes) were similar to those obtained after treatment with semen (compare Tables 1 and 3) , suggesting the same underlying mechanism.
If seminal amyloid accounts for the reduced antiviral efficacies of microbicides, then semen lacking amyloid should not show this effect. To test whether this was indeed the case, we took advantage of the fact that human semen incubated for extended periods of time (≥24 hours) loses the ability to enhance HIV infection (24) . In contrast to regular semen (Table 1) , semen incubated for 48 hours increased the IC 50 values of various microbicides only marginally (Fig. 4 and Table 4 ). To further examine whether semen lacking HIV-enhancing activity does not diminish the antiviral activity of the microbicides, we obtained semen from patients with ejaculatory duct obstruction. Semen from these patients does not enhance HIV infection due to a lack of amyloid (12) . Consistent with the results obtained using the 48-hour-incubated semen samples, semen from patients with ejaculatory duct obstruction did not impair the antiviral activity of cellulose sulfate ( fig. S5) . Unfortunately, the effect on other classes of microbicides could not be determined because only very limited quantities of semen from these patients were available.
In marked contrast to the microbicides discussed thus far, the only anti-HIV compound that was almost equally active against mock-and semen-exposed virus was the CCR5 antagonist maraviroc, which is currently under consideration for microbicide development (25, 26) . Maraviroc inhibited infection of TZM-bl cells by untreated HIV with IC 50 values of 3.7 ± 0.7 nM (0.5 ng of p24) and 3.9 ± 0.2 nM (0.05 ng of p24), respectively, and these values only marginally increased to 4.3 ± 0.3 nM in the presence of semen ( Fig. 5A and Table 1 ). Similarly, exposure of virions to SEVI amyloid fibrils increased the IC 50 values only marginally ( Fig. 5B and Table 3 ). Maraviroc prevented semen-treated HIV infection of TZM-bl cells (Fig. 5A ) and of human PBMCs (Fig. 5C ) at concentrations ranging from 200 to 1000 nM. These concentrations of maraviroc are lower than those detected in the human genital tract (∼2.4 mM in cervicovaginal fluid and ∼1.7 mM in vaginal tissue) after oral administration (27) . Potent inhibition of HIV by maraviroc in the presence of semen was confirmed in a transmission assay examining transmission from cervical epithelial cells (CaSki) to CEMx-M7 indicator cells (Fig. 5D ). Thus, unlike the antiretroviral drugs targeting viral components, maraviroc, an antagonist of the host cell receptor CCR5, maintains potent anti-HIV activity in the presence of semen.
DISCUSSION
Here, we examined whether the HIV infection-promoting effects of semen may explain why many microbicides efficiently inhibit HIV in cell culture but fail to exert protective effects against sexual acquisition of HIV in clinical trials (2-5, 16, 22, 23, 28) . We have shown that brief exposure of HIV to semen reduced the antiviral efficacy of most microbicides by 7-to 22-fold. This was not simply due to different infection rates because the same phenomenon was also observed when mock-and semen-treated HIV was normalized for the same infectivity. Unexpectedly, semen treatment not only reduced the susceptibility of HIV to extracellular microbicides but also conferred significant resistance to reverse transcriptase, integrase, and protease inhibitors that act inside the cell. The only microbicide candidate that remained fully active against semen-treated HIV was maraviroc. This inhibitor of HIV entry was also the only compound that targeted a cellular factor instead of the virus itself. These findings suggest that microbicides targeting viral components are much less effective in the presence of semen, and help to explain the discrepancy between in vitro studies and the outcomes of HIV microbicide clinical trials. Our results do not rule out the possibility that in vivo drug concentrations in the genital tract or rectum that are effective against HIV even in the presence of semen can be reached. However, our data demonstrate that antiviral efficacies of microbicides determined in standard infection assays in the absence of semen may result in misleading results that do not reflect the antiviral potency of the compounds during sexual transmission. Given that semen is the major vector fuelling the global spread of HIV, we recommend preclinical testing of microbicide candidates in vitro with semen-exposed HIV to identify the best candidates for the prevention of HIV transmission by sexual intercourse.
The mechanisms underlying the impaired activity of microbicides against semen-treated HIV need further investigation. It has previously been shown that semen components or the alkaline pH of this body fluid reduces the anti-HIV activity of polyanions by neutralizing their negative charge (29) (30) (31) (32) (33) or by competitive binding to the viral envelope (34) . Although these findings provide conceivable explanations for The nAb 2F5 (A), the nucleotide analog reverse transcriptase inhibitor tenofovir disoproxil fumarate (B), the non-nucleoside reverse transcriptase inhibitor nevirapine (C), and the INI elvitegravir (D) were added to TZM-bl cells, and the protease inhibitor indinavir (E) to CEMx-M7 cells. Cells were inoculated with 0.05 ng of mock-and semen (SE)-exposed HIV, and 0.5 ng of HIV as infectivity-matched control. Infection rates were measured 3 days after infection by measuring b-galactosidase (A to D) or 4 days after infection by measuring luciferase activities. The left panels show the mean enzyme activities ± SD derived from triplicate infections. Middle panels show normalized infection rates in which reporter enzyme activities obtained from infected cells in the absence of inhibitor were set at 100%. The right panels depict the calculated IC 50 values. The number above the bar represents the fold change in the IC 50 derived from 0.05 ng of semen-exposed relative to 0.05 or 0.5 ng of mock-exposed virus infection. ns, no statistically significant difference; ****P < 0.0001; ***P < 0.001 (unpaired t test).
why semen abrogates the antiviral activity of polyanions, they are unlikely to be the only mechanisms. First, the final semen concentrations in our cell culture studies were less than 0.7%, which is too low to directly neutralize the anionic polymers (29) , and second, semen also undermines the efficacy of agents blocking HIV replication through envelope-independent mechanisms that target, for example, the HIV reverse transcriptase, integrase, and protease. Our results clearly show that seminal amyloid is critical for the decreased antiviral efficacy of 50 . ns, no statistically significant difference; ****P < 0.0001; ***P < 0.001 (unpaired t test). the various classes of microbicides because semen lacking HIV-enhancing activity did not impair drug efficacy, whereas synthetic SEVI amyloid fibrils reduced drug efficacy as effectively as semen itself. Because seminal amyloids bind to HIV virions and efficiently enhance and accelerate their attachment to target cells (8, 12, 35, 36) , they shorten the time period of virion exposure to microbicides acting outside the cell and may impede the accessibility of the viral membrane and glycoproteins to polyanions or nAbs. It is less obvious why amyloid fibrils also impair the anti-HIV efficacy of intracellular drugs, particularly because this effect was also observed when mock-and semen-treated HIV were normalized to the same infectivity. Altered infection kinetics may play a key role. Usually, virion attachment is the rate-limiting step during infection (37) . In the presence of amyloid fibrils that capture dozens of virions, all viral particles are attached and concentrated onto the cell surface ( fig. S6) (12, 35, 36, 38) . Thus, only semen-exposed virus may cause simultaneous infection of individual cells, which results in increased viral enzyme production inside the cell. Consequently, higher intracellular levels of antiretroviral drugs are required for effective inhibition of HIV replication. Notably, local increases in the number of virions at cellular entry sites have also recently been suggested to decrease the effectiveness of reverse transcriptase inhibitors during cell-tocell transmission (39) . In contrast to drugs that target viral components, maraviroc inhibits viral entry via binding to the cellular CCR5 receptor. Maraviroc acts as an allosteric inhibitor (40) that renders CCR5 more rigid, and thereby prevents conformational changes that allow HIV to enter cells (41) . Thus, it is conceivable that a saturating drug concentration that occupies all CCR5 molecules at the cell surface prevents HIV entry in a manner that is largely independent of the number of viral particles or the presence of amyloid. Thus, agents targeting cellular factors may be particularly promising for the development of effective microbicides.
To ensure that the impact of semen on the efficacy of microbicides was also relevant for the infection of primary HIV target cells, we performed experiments using human PBMCs. We observed similar effects as in the TZM-bl reporter cells. This was predicted from previous studies demonstrating that semen enhances HIV infection not only of a large variety of cell lines (8, 12, 13, 35) but also of PBMCs (8, 13), macrophages (13, 35) , and endometrial CD4 cells (13) , and also boosts viral transinfection of T cells by dendritic cells or endothelial cells (13) .
We also performed pilot studies in cervicovaginal tissues. However, this experimental system was not suitable to examine the effects of semen on the antiviral efficacy of microbicides because productive HIV infection was variable and required exceedingly high viral doses (42) (43) (44) (45) (46) , whereas enhancing effects of semen were most pronounced at low viral doses (8, 12, 13, 35) . Thus, a limitation of the present study is that it could not test whether the infection-enhancing activity of semen undermined the antiviral efficacy of microbicides at the primary entry portals of HIV. Studies in animal models are required to determine whether semen also undermines the antiretroviral efficacy of microbicides in vivo.
A recent pilot study in macaques suggested that human semen and SEVI did not significantly enhance the efficiency of vaginal simian immunodeficiency virus (SIV) transmission (47), but a major confounding factor in this study was the low number of animals analyzed and their high variability in susceptibility to vaginal SIV infection. This study did, however, provide preliminary evidence that semen and seminal amyloids may facilitate SIV transmission after exposure to low viral doses that most closely approximate the in vivo situation (47) . Thus, further in vivo studies that use chimeric simian/human immunodeficiency virus (SHIV) to study the effects of semen on virus transmission and the efficacy of microbicides are warranted (48) .
In summary, the reduced activity of microbicides that target HIV components against semen-exposed HIV may explain why many compounds that show high efficacy in cell culture infection assays failed in subsequent clinical trials. Maraviroc, however, maintained antiretroviral potency in the presence of semen, suggesting that agents targeting cellular factors may be particularly promising for the development of effective microbicides. Our data also suggest that agents that antagonize seminal amyloid may exert dual beneficial effects because they would (i) prevent enhancement of HIV attachment and infection, and (ii) restore the antiviral activity of other microbicides in the presence of semen. Several agents that abrogate fibril formation or antagonize their HIV-enhancing activity have been described (9-11, 49-52). Thus, combinations of antiretroviral microbicides and agents disrupting the infection-enhancing activity of semen should be more effective than single-component formulations and represent a new strategy for preventing sexual transmission of HIV.
MATERIALS AND METHODS

Study design
We aimed to study the effect of human semen on the antiviral efficacy of antiretroviral drugs and microbicides. De-identified semen samples were obtained, after informed consent, from adult donors presenting at the "Kinderwunschzentrum Ulm," a fertility center in Ulm, Germany. After ejaculation, samples were allowed to liquefy for about 30 min, pooled, aliquoted, and frozen at −20°C. Experiments were performed with freshly thawed aliquots and were approved by the local ethics committee at Ulm University (proposal numbers 351/10 and 156/13). Serial dilutions of antiviral compounds targeting different steps in the viral life cycle were added to TZM-bl and CEMx-M7 reporter cells, which were subsequently inoculated with HIV that was treated with buffer, semen, or synthetic seminal amyloid. Infection rates were determined by measuring b-galactosidase (TZM-bl) and luciferase (CEMx-M7) activities in luminescence-based assays 3 to 4 days after infection. Similar experiments were performed in primary PBMCs that were inoculated with a luciferase-encoding virus. All experiments were performed in triplicate, and the results were confirmed in at least one independent experiment. Data were evaluated by a statistician.
Reagents
Cellulose sulfate, polystyrene acid, and polynaphthalene sulfonate were obtained from Acros Organics, Polysciences Inc., and BASF, respectively. SPL7013, the active ingredient of VivaGel, was obtained from Starpharma and dissolved in phosphate-buffered saline (PBS) (100 mg/ml). Monoclonal antibodies (2F5, 2G12) were purchased from Polymun. Maraviroc was obtained from Pfizer. Nevirapine, tenofovir disoproxil fumarate, and elvitegravir were purchased from Selleckchem. Indinavir was provided by the National Institutes of Health AIDS Research and Reference Reagent Program (ARRRP). SEVI was generated as described (8) .
Cell culture Adherent TZM-bl reporter cells (ARRRP) containing lacZ reporter genes under the control of the HIV LTR (long terminal repeat) promoter and suspension CEMx-M7 cells (ARRRP) containing the gene encoding firefly luciferase under the control of the HIV LTR promoter were cultured as described (12) . Human PBMCs were prepared as described (8) . Unless noted otherwise, all media contained 10% fetal bovine serum, penicillin/ streptomycin, L-glutamine, and gentamicin (50 mg/ml) (Gibco).
Infection of TZM-bl cells by mock-or semen-treated HIV in the presence of microbicides Briefly, liquefied semen derived from >20 de-identified donors was pooled. Semen samples from de-identified patients with ejaculatory duct obstruction were provided by O. Sorensen (Lund University, Sweden). To examine the activity of candidate microbicides in the presence of semen, 5 × 10 3 TZM-bl cells were seeded into 96-well flat-bottom plates (100 ml). The next day, when cells were ∼70% confluent, the medium was replaced by fresh medium (250 ml) in the presence of antivirals (30 ml). After 1 hour of incubation, semen was mixed 1:1 (v/v) with virus to obtain semen concentrations of 10% during virion treatment. Viral stocks of R5-tropic HIV-1 NL4-3_92TH014.12 or T/F viruses were obtained by transient transfection of 293T cells with proviral DNA and were titrated on TZM-bl cells (8, 17) . After incubating the semen/virus mixture for 5 min, 20 ml of the semenvirus (or PBS-virus control) were then added to compound-treated cells (volume, 280 ml). Final cell culture concentrations of semen were 0.67 and 0%. We used a viral multiplicity of infection (MOI) of ∼0.05 (corresponding to 0.05 ng of p24 antigen of HIV-1 NL4-3_92TH014.12), which gives a low but consistently detectable level of infection in the absence of semen. This MOI allowed us to detect an enhancing effect of semen, as assessed by an increase in the numbers of infected cells. Furthermore, we used an MOI ∼0.5 (corresponding to 0.5 ng of p24 antigen of HIV-1 NL4-3_92TH014.12), which gives the same detectable level of background infection as a low MOI in the presence of semen. This high MOI is necessary to compare the inhibitory effect of the microbicides in the presence and absence of semen, as assessed by a decrease in the numbers of infected cells. After 2 hours of incubation, cells were washed and further cultivated in 200 ml of fresh medium supplemented with the microbicides. The addition of gentamicin was crucial to prevent bacterial growth. Three days later, infection rates were measured using the Gal-Screen system (Applied Biosystems).
Infection of PBMCs by mock-or semen-treated HIV in the presence of microbicides PBMCs were isolated and prepared as described (8) . An R5-tropic HIV NL4-3 construct expressing a luciferase was generated by transient transfection of 293T cells as described (8) . Activated PBMCs (2 × 10 5 ) were preincubated with compounds in 280 ml of RPMI medium for 1 hour. Cells were then infected with 20 ml of 10% semen-or mockexposed virus containing either 5 or 50 ng of p24 antigen. To remove the cytotoxic semen inoculums, cells were transferred to V-shaped microtiter plates after 2 hours and pelleted at 1000 rpm for 5 min. Supernatants were removed, and cells were resuspended in 180 ml of fresh medium with 20 ml of the candidate microbicides. Gaussia-luciferase activities were determined 3 days later. A 1-mg coelenterazine substrate solution was prepared by adding coelenterazine to acidified methanol. The substrate was then diluted 1:170 in dilution buffer (0.1 M tris, 0.3 M sodium ascorbate, pH 7.4). Twenty microliters of PBMC supernatants was then mixed with 80 ml of Gaussia substrate, and luminescence was recorded on an Orion microplate luminometer as relative light units per second. To determine the antiviral activity of indinavir, cells were pelleted 2 days after infection and further cultivated in 200 ml of fresh medium supplemented with the microbicides. Supernatants obtained at day 4 after infection were then assayed for Gaussia-luciferase activity as described above.
Infection of CEMx-M7 cells by mock-or semen-treated HIV in the presence of a protease inhibitor To examine the activity of the protease inhibitor indinavir, 2 × 10 5 CEMx-M7 cells were seeded into 96-well, V-shaped plates (250 ml). Then, 30 ml of antivirals was added and incubated for 1 hour. Semen was mixed 1:1 (v/v) with virus to obtain semen concentrations of 10% during virion treatment. After incubating the semen-virus mixture for 5 min, 20 ml of the semen-virus (or PBS-virus control) was added to compound-treated cells (volume, 280 ml). Final cell culture concentrations of semen were 0.67 and 0%. After 2 hours of incubation, cells were washed and further cultivated in 200 ml of fresh medium supplemented with the microbicides. Two days after infection, cells were pelleted and further cultivated in 200 ml of fresh medium supplemented with the microbicides. Four days later, infection rates were measured using the Luciferase Assay System (Promega).
Infection of TZM-bl cells by mock-or SEVI-treated HIV in the presence of microbicides SEVI was generated as described (8) . To analyze the activity of candidate microbicides in the presence of SEVI, 5 × 10 3 TZM-bl cells were seeded into 96-well flat-bottom plates (100 ml). The next day, when cells were ∼70% confluent, the medium was replaced by fresh medium (160 ml) in the presence of antivirals (20 ml). After 1 hour of incubation, SEVI was mixed 1:1 (v/v) with virus to obtain SEVI concentration of 35 mg/ml during virion treatment. After incubating the SEVI-virus mixture for 5 min, 20 ml of the SEVI-virus (or PBS-virus control) was then added to compound-treated cells (volume, 180 ml). Three days later, infection rates were measured using the Gal-Screen system (Applied Biosystems). The effect of SEVI on the antiviral activity of the protease inhibitor was analyzed in CEMx-M7 cells essentially as described above for the analysis of semen, except that virions were treated with SEVI (35 mg/ml) instead of semen.
Infection of TZM-bl cells by HIV treated with semen devoid of its HIV-enhancing activity in the presence of microbicides Semen samples from de-identified individuals were incubated at 37°C for 48 hours, resulting in a loss of infectivity-enhancing activity (24) . TZM-bl cells (5 × 10 3 ) were seeded into 96-well flat-bottom plates (100 ml), and the next day, when cells were ∼70% confluent, media were replaced with fresh media (250 ml) in the presence of antivirals (30 ml). After 1 hour of incubation, incubated semen was mixed 1:1 (v/v) with virus to obtain semen concentrations of 10% during virion treatment. After incubating the semen-virus mixture for 5 min, 20 ml of the semenvirus (or PBS-virus control) was added to compound-treated cells (volume, 280 ml). Final cell culture concentrations of semen were 0.67 and 0%. After 2 hours of incubation, cells were washed and further cultivated in 200 ml of fresh medium supplemented with the microbicides. Three days later, infection rates were measured using the Gal-Screen system (Applied Biosystems).
Cell-to-cell transmission CaSki cells (1 × 10 4 ) (epithelial cervical carcinoma cell line) were seeded in 250 ml of medium and incubated overnight. The next day, the cells were preincubated with the indicated concentrations of candidate microbicides (30 ml) for 1 hour and then inoculated with 20 ml of semen-treated HIV (92TH014.12) for 2 hours. Inoculum was then removed, and 5 × 10 4 CEMx-M7 cells were added onto the CaSki cells in the presence of the candidate microbicides. The antiviral activity of candidate microbicides was determined by measuring luciferase activity as described above.
Cell viability
The effect of semen on metabolic activity of cells was analyzed using the MTT assay under experimental conditions corresponding to those used in the respective infection assays. To assess cell viability for each compound, 1 × 10 4 TZM-bl cells (in 180 ml) were incubated with 20 ml of the indicated compounds to achieve the indicated final concentration. After 3 days of incubation, 20 ml of MTT [3-(4,5-dimethylthiazole-2-yl)-2,5 diphenyltetrazolium bromide, Sigma #M2003] solution (5 mg/ml) was added to cells. After 3 hours, the cell-free supernatant was discarded, formazan crystals were dissolved in 100 ml of dimethyl sulfoxide (DMSO)-ethanol (1:1), and optical density was detected at 490/650 nm. The percent viability rates were calculated relative to NAD(P)H (reduced form of nicotinamide adenine dinucleotide phosphate)-dependent cellular oxidoreductase activity in PBS-treated cells (100%).
IC 50 calculation and statistical analysis
For each compound, IC 50 s were calculated using the dose-response inhibition model in GraphPad Prism software (version 5.03). All statistical analyses were calculated in the R software using an unpaired t test, which compared the mean IC 50 values derived from three replicate experiments. All results are represented as means ± SD. ns, no statistically significant difference, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
SUPPLEMENTARY MATERIALS
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